Avicanna Inc.
AVCN.TO
Get informed when a big investor buys or sells
+ FollowMarket Cap$14.47M
Close$
Share Statistics
| Market cap | $14.47 Million |
|---|---|
| Enterprise Value | $14.81 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.02 |
| Beta | 0.35 |
| Outstanding Shares | 126,240,746 |
Return
| Return on Equity | -84.99% |
|---|---|
| Return on Assets | -16.21% |
| Return on Invested Capital | -25.79% |
Valuation & Multiples
| P/E Ratio | -3.55 |
|---|---|
| PEG | -7.77 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.59 |
| Enterprise Value to EBIT | -3.96 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$-0.04
Average shareholder expectationRevenue Estimate
$3.00 M
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-0.04
Average shareholder expectationRevenue Estimate
$3.00 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Avicanna Inc.
112 employees
CEO: Aras Azadian Mba Avicanna Inc. is a biopharmaceutical company already in its commercial phase, dedicated to the research and development of scientifically-backed products for global consumer health and pharmaceutical sectors. It maintains partnerships wi...